Please use this identifier to cite or link to this item:
Title: Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older.
Austin Authors: Seeman, Ego ;Vellas, Bruno;Benhamou, Claude;Aquino, Jean Pierre;Semler, Jutta;Kaufman, Jean Marc;Hoszowski, Krzysztof;Varela, Alfredo Roces;Fiore, Carmelo;Brixen, Kim;Reginster, Jean Yves;Boonen, Steven
Affiliation: Austin Hospital, University of Melbourne, Australia
Issue Date: 1-Jul-2006
Publication information: Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research; 21(7): 1113-20
Abstract: Strontium ranelate produces an early and sustained reduction of both vertebral and nonvertebral fractures in patients > or = 80 years of age.About 25-30% of the population burden of all fragility fractures in the community arise from women > or = 80 years of age, because this population is at high risk for all types of fracture, particularly nonvertebral fractures. Despite this, evidence that therapies reduce the risk of both vertebral and nonvertebral fractures in this group is lacking. The aim of this study was to determine whether strontium ranelate, an agent that reduces the risk of vertebral and nonvertebral fractures in postmenopausal women >50 years of age, also reduces fractures in the elderly.An analysis based on preplanned pooling of data from two international, phase III, randomized, placebo-controlled, double-blind studies (the Spinal Osteoporosis Therapeutic Intervention [SOTI] and TReatment Of Peripheral OSteoporosis [TROPOS]) included 1488 women between 80 and 100 years of age followed for 3 years. Yearly spinal X-rays were performed in 895 patients. Only radiographically confirmed nonvertebral fractures were included.Baseline characteristics did not differ in placebo and treatment arms. In the intent-to-treat analysis, the risk of vertebral, nonvertebral, and clinical (symptomatic vertebral and nonvertebral) fractures was reduced within 1 year by 59% (p = 0.002), 41% (p = 0.027), and 37% (p = 0.012), respectively. At the end of 3 years, vertebral, nonvertebral, and clinical fracture risks were reduced by 32% (p = 0.013), 31% (p = 0.011), and 22% (p = 0.040), respectively. The medication was well tolerated, and the safety profile was similar to that in younger patients.Treatment with strontium ranelate safely reduces the risk of vertebral and nonvertebral fractures in women with osteoporosis > or = 80 years of age. Even in the oldest old, it is not too late to reduce fracture risk.
Gov't Doc #: 16813532
DOI: 10.1359/jbmr.060404
Journal: Journal of Bone and Mineral Research
Type: Journal Article
Subjects: Age Factors
Aged, 80 and over
Double-Blind Method
Fractures, Bone.prevention & control
Organometallic Compounds.administration & dosage
Osteoporosis, Postmenopausal.complications.drug therapy
Retrospective Studies
Risk Factors
Spinal Fractures.etiology.prevention & control
Spine.drug effects
Thiophenes.administration & dosage
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Apr 12, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.